Leukemia: all 5,475 studies
Page 43 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid LeukemiaTerminatedNCT00895297Phase 2
- Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
- Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of AgeCompletedNCT00893373Phase 2
- Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic LeukemiaStatus unknownNCT00892827Phase 2
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic SyndromeCompletedNCT00892190Phase 1
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyCompletedNCT00891137Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical TrialCompletedNCT00890435
- Tumor Registry of Lymphatic NeoplasiaCompletedNCT00889798
- DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or LymphomaCompletedNCT00889408Phase 1
- Protocol to Obtain Blood Samples for Leukemia ResearchCompletedNCT00889031
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AMLStatus unknownNCT00887042Phase 1/2
- Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and NeutropeniaWithdrawnNCT00886496Phase 1
- A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
- Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute LeukemiasTerminatedNCT00882076Phase 1
- Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALLActive, not recruitingNCT00881920Phase 1
- Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)CompletedNCT00880243Phase 3
- A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
- Rapamycin in Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00874562Phase 1
- Study of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaWithdrawnNCT00872976Phase 1
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)TerminatedNCT00871546Phase 2
- The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)Status unknownNCT00868478Phase 1/2
- Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00868413Phase 1
- Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid LeukemiaCompletedNCT00867672Phase 2
- FTS Study in Patients With Advanced Hematologic MalignanciesCompletedNCT00867230Phase 1
- A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid LeukemiaCompletedNCT00866736Phase 2
- Observational Study of Nelarabine in Children and Young AdultsCompletedNCT00866671
- PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic TransplantationWithdrawnNCT00866346Phase 1
- Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid LeukemiaCompletedNCT00866073Phase 2
- Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)CompletedNCT00864942Phase 1
- A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00861874Phase 1
- Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation InternationalCompletedNCT00861679Not applicable
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
- Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate RiskCompletedNCT00860639Phase 3
- JVRS-100 for the Treatment of Patients With Relapsed or Refractory LeukemiaCompletedNCT00860522Phase 1
- Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib TherapyCompletedNCT00858806Phase 2
- Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2
- Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
- Treatment of High Risk Adult Acute Lymphoblastic LeukemiaCompletedNCT00853008Phase 4
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedNCT00852566Phase 2
- Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan RegimenCompletedNCT00852163Phase 2
- Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1/2
- Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic TrioxideCompletedNCT00850304Phase 2
- Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT00850057Phase 1
- Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
- The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic LeukemiaStatus unknownNCT00846703Phase 4
- Glivec in Pediatric Chronic Myeloid Leukemia (CML)CompletedNCT00845221Phase 4
- Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To TreatmentWithdrawnNCT00845104Phase 2
- Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00844441Not applicable
- Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00840684Phase 1/2
- Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
- Lenalidomide In Patients With Acute Myeloid LeukemiaTerminatedNCT00839059Phase 1
- Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk MyelodysplasiaStatus unknownNCT00838240Phase 1/2
- Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic LeukemiaTerminatedNCT00836043
- Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00834002Phase 1
- Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantWithdrawnNCT00833534Phase 2
- A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic LeukemiaWithdrawnNCT00829647Phase 1/2
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)CompletedNCT00827138Phase 1
- Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced CancerCompletedNCT00823524Phase 1/2
- ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG AsparaginaseCompletedNCT00819351Phase 3
- Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological CancerWithdrawnNCT00816413Phase 1/2
- Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1
- ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation TherapyCompletedNCT00816049Phase 3
- Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug TherapyCompletedNCT00815321Phase 2
- Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other DiseasesTerminatedNCT00813501
- CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7CompletedNCT00812669Phase 2
- Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)Status unknownNCT00810680Not applicable
- Collection and Banking of Leukemia Cells MDS/AMLCompletedNCT00809367Not applicable
- Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
- Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00809211Phase 2
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
- Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerCompletedNCT00806767Phase 2
- Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid LeukemiaCompletedNCT00806325
- My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid LeukemiaStatus unknownNCT00801580Phase 2
- Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in RemissionCompletedNCT00801346
- Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00801060Phase 2
- Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After ChemotherapyStatus unknownNCT00800943Phase 2
- Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00800566Phase 1
- Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to TreatmentTerminatedNCT00800150Phase 1
- Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer CellsStatus unknownNCT00799799Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)TerminatedNCT00798213Phase 2
- Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid LeukemiaCompletedNCT00797758Phase 2
- Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic LeukemiaCompletedNCT00795756Phase 2/3
- Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell TransplantationCompletedNCT00795548Phase 2
- Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaTerminatedNCT00792831Phase 2
- Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00786812Phase 4
- Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic LeukaemiaCompletedNCT00784017Phase 3
- A Phase I Extension Trial of Repeated Infusions of ISF35CompletedNCT00783588Phase 1
- A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their FamiliesCompletedNCT00782145Phase 3
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AMLCompletedNCT00780598Phase 2
- Sirolimus in Combination With MEC in High Risk Myeloid LeukemiasCompletedNCT00780104Phase 1
- A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)CompletedNCT00779883Phase 1
- Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)TerminatedNCT00779480Phase 1
- Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning RegimenCompletedNCT00774280Phase 3
- Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic LeukemiaCompletedNCT00773149Phase 1/2
- Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple MyelomaCompletedNCT00772811Phase 2
- A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLLCompletedNCT00772486Phase 1
- Perceptions of Burden in Patients With Late-Stage Cancer and Their CaregiversWithdrawnNCT00770419